Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
about
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectivesImmunostimulatory Gene Therapy Using Oncolytic Viruses as VehiclesThe Concept of Hormesis in Cancer Therapy - Is Less More?Tregs in infection and vaccinology: heroes or traitors?Vaccines for pancreatic cancerCombining radiotherapy and cancer immunotherapy: a paradigm shiftScience gone translational: the OX40 agonist storyMeasles to the Rescue: A Review of Oncolytic Measles VirusAutophagy, autophagy-associated adaptive immune responses and its role in hematologic malignanciesThe intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancerImmunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axisIntratumoral Lentivector-Mediated TGF-β1 Gene Downregulation As a Potent Strategy for Enhancing the Antitumor Effect of Therapy Composed of Cyclophosphamide and Dendritic CellsMetronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma modelFrom promotion to management: the wide impact of bacteria on cancer and its treatmentGut microbiome and anticancer immune response: really hot Sh*t!Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein.Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cellsCombinatorial strategies for the induction of immunogenic cell death.Gene and cell therapy for pancreatic cancer.Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastomaMetronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memoryThe influence of gut microbiota on drug metabolism and toxicity.Targeting the Immune System to Fight Cancer Using Chemical Receptor Homing Vectors Carrying Polyinosine/Cytosine (PolyIC).Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.Why has active immunotherapy not worked in lung cancer?Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancerTreatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4⁺ T cell response against MC38 colon carcinomaThrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome.Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibodyNanocarrier-based immunotherapy in cancer management and research.Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with ProdrugsEffective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer.Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy.Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.
P2860
Q26751280-BB819128-7BFC-4307-9D24-E7C405B94615Q26777403-25C078AC-ACF6-49EF-BA5F-62A66E8D7A67Q26800519-246DD879-06EB-41CB-9A66-6828260F2DE6Q26822874-160D1E40-5627-4A86-8F86-E256809711D3Q26825850-32CA20AE-4513-4618-AB13-41C407DA2B2BQ27021428-BB5B88D1-34B2-42E5-8D3E-E312B7CE7ACFQ27022436-37C2629C-621E-4651-A4E2-35E403C4ADFAQ28072097-55B54F17-7CF8-4A4B-8A43-3282EB51D1A3Q28072922-61FBC3E0-BA5F-4CA6-8624-88BDAE3BA4A9Q31144277-94C4087A-ACA4-4B5A-B0AB-DFCC7C8B6AECQ33738937-0E290B06-F523-43F3-A1FB-C706F3EE29A1Q33838944-1417EFD3-6D26-425C-B08C-958FC25239FEQ33858506-786B2A21-A542-4C28-B799-37A64CD25E74Q34173568-3F7F3DD1-FE56-4410-9B08-328CF8A22405Q34263890-D85EFFF7-9DE7-4B1F-AED9-941494E06C37Q34924272-6623A640-2A9D-4387-AB1E-BE40357B9DD1Q35053658-33965228-7540-4C51-BBF1-E388A85C2981Q35071850-C0F93132-9913-4F8A-B48A-D48DA44CA5F1Q35535140-C1B6482F-6768-4A68-A47C-49FDD9E29372Q35541787-E700771B-6103-40A7-8B13-9A4162602176Q35747826-DB9B095F-A619-4542-94F5-16141A59CC21Q35799297-F0DC76B6-2179-4439-80FD-B57E6DD0D112Q35841503-486305CE-E7CB-498D-8140-33EFFD47D84BQ35971366-BBE4BC34-026C-4452-B4CB-9F380AA04C4CQ36173622-C7DDF8DB-FF23-4056-B0C1-0B160F1AFCE3Q36207901-C1C2545E-F591-440C-A011-57D40C586045Q36249440-A8911651-87F8-4E6D-B5B9-2420F8EAB08CQ36287976-E9D1DC89-3F92-47DF-8202-1DD1BAA15A3DQ36388495-1A65351E-7A8E-41C0-8F2C-24C4F3640130Q36476394-4E8CDEA3-12F6-4AB2-871F-422407907F05Q36498103-F9FA86FA-D5CB-4B05-82E3-3DA44B985D05Q36586178-D6F989A6-2C70-469E-817D-8AE22EF768BBQ36694931-922572EC-1936-4D56-ADE4-CF2A3B9B7E79Q36884975-8A56D952-3ADC-4D2C-BC6C-6273747E54B1Q36923046-9210BF5C-8B64-4D72-AC22-84E94B74859CQ37031671-D61007A8-552B-4130-BA14-CC4FD6371109Q37138701-08DDB495-4D8C-4B5B-AAA6-AC80C46F9E93Q37459043-4758FC6D-006E-41F6-8997-0E6ED66DDC8EQ37520816-B1170ADF-2AA8-4931-927A-14AB2EE1B9CCQ37722551-2BCC2D05-D702-488B-9F8C-721F31CF603D
P2860
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@ast
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@en
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@nl
type
label
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@ast
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@en
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@nl
prefLabel
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@ast
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@en
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@nl
P2860
P50
P1476
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.
@en
P2860
P2888
P304
P356
10.1007/S00281-011-0245-0
P577
2011-05-25T00:00:00Z
P6179
1006731314